Use VigiFlow to support your vaccine safety surveillance in a timely and efficient manner.
Monitoring adverse events following immunisation (AEFI) is an essential strategy for ensuring the safety of vaccines. In response to the COVID-19 pandemic, we’re increasing support for vaccine safety surveillance in UMC’s pharmacovigilance products.
VigiFlow supports national vaccine safety surveillance, allowing rapid identification of any safety concern regarding vaccines.
In collaboration with WHO and other stakeholders, we have recently expanded VigiFlow to support facilitated reporting and analysis of adverse events following immunisation (AEFI) for immunisation programmes (at district, provincial, and national levels). The AEFI expansion provides support for data capture (including the core variables for AEFI) and analysis facilitated by a customised line listing. VigiFlow also supports reporting statistics and controlled sharing of reports with the WHO Programme for International Drug Monitoring (PIDM).
We will continue refining the development with a focus on supporting effective vaccine safety surveillance as a complement to the existing ICSR management support.
As an introduction, we have prepared a series of short videos showing how to enter and analyse the AEFI data in VigiFlow.
There is also a quick start guide, aimed at new VigiFlow users from immunization programmes to quickly get started in the system.
In addition, recordings of training webinars focusing of the new data entry form, WHODrug coding aspects of COVID-19 vaccines, and the AEFI line listing are available here:
Through the secure and controlled sharing of information from VigiFlow to Vigibase, VigiLyze facilitates investigation of safety concerns with support from the national, regional, and global data available in Vigibase. The recent VigiLyze developments, by focusing on increasing the support for vaccine safety surveillance, enable members of the WHO Programme for International Drug Monitoring to now do more advanced statistical signal detection work, vaccine by vaccine, as well as analyse different vaccine platforms. Read more about Vigilyze here.
Explore these improvements and possibilities in VigiFlow together with us. Please contact email@example.com for more information and support.
This site will be continuously updated with new information as it becomes available.